{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:10:05Z","timestamp":1756375805522,"version":"3.44.0"},"reference-count":21,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,7,21]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>This case presentation outlines the occurrence of primary adrenal insufficiency secondary to ATP binding cassette subfamily D member 1 (ABCD1) mutation in a man in his 40s following a genetic screening test performed after a diagnosis of X-linked adrenoleukodystrophy (X-ALD) in his nephew who is in his middle childhood years. In contrast to his nephew\u2019s presentation with rapid onset and progression of cerebral adrenoleukodystrophy leading to severe neurological manifestations, his symptoms primarily included chronic fatigue and muscle stiffness without any features suggestive of mineralocorticoid deficiency noted for at least 3 years preceding the timeline of his diagnosis. Genetic testing revealed X-ALD (hemizygous for ABCD1:c901-5c&gt;A). A short synacthen test confirmed primary adrenocortical insufficiency. Hydrocortisone treatment was initiated, leading to improvement in symptoms. His presentation highlights the well-recognised but less commonly perceived implications of ABCD1 mutation and its relevance in routine clinical practice as a part of diagnostic tests for primary adrenal insufficiency.<\/jats:p>","DOI":"10.1136\/bcr-2025-265277","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T18:05:19Z","timestamp":1754330719000},"page":"e265277","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Incidental diagnosis of primary adrenal insufficiency precipitated by positive ABCD1 gene mutation detected on cascade screening"],"prefix":"10.1136","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3690-8139","authenticated-orcid":false,"given":"Jovito","family":"Chacko James","sequence":"first","affiliation":[{"name":"Diabetes, Endocrinology and General (Internal) Medicine, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, Staffordshire, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9147-2950","authenticated-orcid":false,"given":"Athira","family":"Mukunda","sequence":"additional","affiliation":[{"name":"Diabetes, Endocrinology and General (Internal) Medicine, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, Staffordshire, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhea","family":"Jacob","sequence":"additional","affiliation":[{"name":"King Edward VI Camp Hill School for Girls, Birmingham, England, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antony Mosses","family":"George","sequence":"additional","affiliation":[{"name":"Diabetes, Endocrinology and General (Internal) Medicine, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, Staffordshire, UK"},{"name":"Clinical Education Centre, Keele University, Newcastle-under-Lyme, England, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"2025082802374222000_18.8.e265277.1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/ncpneuro0421","article-title":"X-linked adrenoleukodystrophy","volume":"3","author":"Moser","year":"2007","journal-title":"Nat Rev Neurol"},{"key":"2025082802374222000_18.8.e265277.2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4331\/wjbc.v11.i3.99","article-title":"Deciphering the modifiers for phenotypic variability of X-linked adrenoleukodystrophy","volume":"11","author":"Palakuzhiyil","year":"2020","journal-title":"WJBC"},{"key":"2025082802374222000_18.8.e265277.3","unstructured":"Alsaleem M , Haq N , Saadeh L . Adrenoleukodystrophy.Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK562328"},{"key":"2025082802374222000_18.8.e265277.4","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.720769","article-title":"Latent Adrenal Insufficiency: From Concept to Diagnosis","volume":"12","author":"Younes","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025082802374222000_18.8.e265277.5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jns.2014.09.015","article-title":"Adult-onset spastic paraparesis: an approach to diagnostic work-up","volume":"346","author":"Zhovtis Ryerson","year":"2014","journal-title":"J Neurol Sci"},{"key":"2025082802374222000_18.8.e265277.6","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-244757","article-title":"Adult-onset adrenoleukodystrophy presenting with status epilepticus and psychosis","volume":"14","author":"Mehta","year":"2021","journal-title":"BMJ Case Rep"},{"key":"2025082802374222000_18.8.e265277.7","unstructured":"Kemp S , Berger J , Aubourg P . The abcd1 variant registry. X-ALD Mutation Database. n.d. Available: https:\/\/adrenoleukodystrophy.info\/mutations-and-variants-in-abcd1"},{"key":"2025082802374222000_18.8.e265277.8","unstructured":"Vlachou S , Kanakis G , Kaltsas G . Adrenal Insufficiency Due to X-Linked Adrenoleukodystrophy.Available: https:\/\/www.ncbi.nlm.nih.gov\/sites\/books\/NBK278944"},{"key":"2025082802374222000_18.8.e265277.9","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1212\/WNL.0000000000201374","article-title":"International Recommendations for the Diagnosis and Management of Patients With Adrenoleukodystrophy: A Consensus-Based Approach","volume":"99","author":"Engelen","year":"2022","journal-title":"Neurology (ECronicon)"},{"key":"2025082802374222000_18.8.e265277.10","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.11.2009.2419","article-title":"X-linked adrenoleukodystrophy presenting as Addison\u2019s disease","volume":"2010","author":"Morell","year":"2010","journal-title":"BMJ Case Rep"},{"key":"2025082802374222000_18.8.e265277.11","article-title":"An unusual presentation of X-linked adrenoleukodystrophy","volume":"2015","author":"Suryawanshi","year":"2015","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2025082802374222000_18.8.e265277.12","doi-asserted-by":"publisher","DOI":"10.1007\/BF01799621"},{"key":"2025082802374222000_18.8.e265277.13","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410360617"},{"key":"2025082802374222000_18.8.e265277.14","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/ajmg.a.61171","article-title":"A report on state-wide implementation of newborn screening for X-linked Adrenoleukodystrophy","volume":"179","author":"Wiens","year":"2019","journal-title":"Am J Med Genet A"},{"key":"2025082802374222000_18.8.e265277.15","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrendo.2016.90","article-title":"Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history","volume":"12","author":"Kemp","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"2025082802374222000_18.8.e265277.16","doi-asserted-by":"crossref","first-page":"107734","DOI":"10.1016\/j.ymgme.2023.107734","article-title":"Newborn screening for adrenoleukodystrophy: International experiences and challenges","volume":"140","author":"Videb\u00e6k","year":"2023","journal-title":"Mol Genet Metab"},{"key":"2025082802374222000_18.8.e265277.17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/ijns8010016","article-title":"Newborn Screening for X-Linked Adrenoleukodystrophy: Past, Present, and Future","volume":"8","author":"Moser","year":"2022","journal-title":"IJNS"},{"key":"2025082802374222000_18.8.e265277.18","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1219324","article-title":"Adult-onset leukodystrophies: a practical guide, recent treatment updates, and future directions","volume":"14","author":"Muthusamy","year":"2023","journal-title":"Front Neurol"},{"key":"2025082802374222000_18.8.e265277.19","unstructured":"Eichler F . Benefits of gene therapy for cerebral ALD persist at long-term follow-up. NeuroToday 2024. Available: https:\/\/journals.lww.com\/neurotodayonline\/fulltext\/2024\/11210\/benefits_of_gene_therapy_for_cerebral_ald_persist.9.aspx"},{"key":"2025082802374222000_18.8.e265277.20","doi-asserted-by":"crossref","first-page":"1309053","DOI":"10.3389\/fendo.2023.1309053","article-title":"X-linked adrenoleukodystrophy and primary adrenal insufficiency","volume":"14","author":"Cappa","year":"2023","journal-title":"Front Endocrinol"},{"key":"2025082802374222000_18.8.e265277.21","unstructured":"NHS England . Allogeneic haematopoietic stem cell transplant for patients with x-linked cerebral adrenoleukodystrophy (adults): clinical commissioning policy. London NHS England; 2023. Available: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2023\/11\/2203-allogeneic-haematopoietic-stem-cell-transplant-cc-policy.pdf"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-265277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:37:50Z","timestamp":1756373870000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-265277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":21,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,4]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bcr-2025-265277"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-265277","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}